| Riverview Healthcare Center | |
| 611 East 2nd Ave, Flandreau, South Dakota 57028 | |
| (605) 997-2481 | |
| Name | Riverview Healthcare Center |
|---|---|
| Location | 611 East 2nd Ave, Flandreau, South Dakota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 63 |
| Occupancy Rate | 54.13% |
| Medicare ID (CCN) | 435086 |
| Legal Business Name | Empres At Flandreau Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1356740849 |
| Organization Name | FLANDREAU HEALTHCARE, LLC |
| Address | 611 E 2nd Ave, Flandreau, SD 57028 |
| Phone Number | 608-997-2481 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.
Brazos Private Equity Partners, LLC, a leading Dallas-based private investment firm, today announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, Inc., a subsidiary of Paris-based Essilor International and the leading manufacturer and wholesale distributor of optical lenses in the United States.
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture "From a Neuroscience of Pain to a Neuroethics of Care" by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.
› Verified 4 days ago
| NPI Number | 1518969203 |
| Organization Name | RIVERVIEW HEALTH SERVICES, INC |
| Address | 611 E 2nd Ave, Flandreau, SD 57028 |
| Phone Number | 605-997-2481 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.
Brazos Private Equity Partners, LLC, a leading Dallas-based private investment firm, today announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, Inc., a subsidiary of Paris-based Essilor International and the leading manufacturer and wholesale distributor of optical lenses in the United States.
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture "From a Neuroscience of Pain to a Neuroethics of Care" by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.
› Verified 4 days ago
| NPI Number | 1982176764 |
| Organization Name | EMPRES AT FLANDREAU, LLC |
| Address | 611 E 2nd Ave, Flandreau, SD 57028 |
| Phone Number | 605-997-2481 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.
Brazos Private Equity Partners, LLC, a leading Dallas-based private investment firm, today announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, Inc., a subsidiary of Paris-based Essilor International and the leading manufacturer and wholesale distributor of optical lenses in the United States.
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture "From a Neuroscience of Pain to a Neuroethics of Care" by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.
Brazos Private Equity Partners, LLC, a leading Dallas-based private investment firm, today announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, Inc., a subsidiary of Paris-based Essilor International and the leading manufacturer and wholesale distributor of optical lenses in the United States.
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture "From a Neuroscience of Pain to a Neuroethics of Care" by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.13 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 13.79 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.43 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.06 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 4.38 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 22.62 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.2 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.11 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 18.67 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 20.63 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 17.09 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.81 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.55 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 91.28 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 92.78 | 82.93 |
News Archive
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.
Brazos Private Equity Partners, LLC, a leading Dallas-based private investment firm, today announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, Inc., a subsidiary of Paris-based Essilor International and the leading manufacturer and wholesale distributor of optical lenses in the United States.
An international consortium of scientists led by a group from the University of Leicester has announced a new advance in understanding the mechanisms of cancer and how to target it more effectively with new treatments.
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture "From a Neuroscience of Pain to a Neuroethics of Care" by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.
› Verified 4 days ago
Riverview Healthcare Center Location: 611 East 2nd Ave, Flandreau, South Dakota 57028 Phone: (605) 997-2481 |